- Home
- RNAZ vs GLMD Comparison
RNAZ vs GLMD Comparison
Compare RNAZ & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- GLMD
- Stock Information
- Founded
- RNAZ 2016
- GLMD 2000
- Country
- RNAZ United States
- GLMD Israel
- Employees
- RNAZ N/A
- GLMD N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- RNAZ Health Care
- GLMD Health Care
- Exchange
- RNAZ Nasdaq
- GLMD Nasdaq
- Market Cap
- RNAZ 4.9M
- GLMD 4.6M
- IPO Year
- RNAZ 2021
- GLMD 2014
- Fundamental
- Price
- RNAZ $3.84
- GLMD $2.95
- Analyst Decision
- RNAZ Strong Buy
- GLMD
- Analyst Count
- RNAZ 1
- GLMD 0
- Target Price
- RNAZ $20.00
- GLMD N/A
- AVG Volume (30 Days)
- RNAZ 69.9K
- GLMD 41.8K
- Earning Date
- RNAZ 11-14-2024
- GLMD 12-27-2024
- Dividend Yield
- RNAZ N/A
- GLMD N/A
- EPS Growth
- RNAZ N/A
- GLMD N/A
- EPS
- RNAZ N/A
- GLMD N/A
- Revenue
- RNAZ N/A
- GLMD N/A
- Revenue This Year
- RNAZ N/A
- GLMD N/A
- Revenue Next Year
- RNAZ $233.33
- GLMD N/A
- P/E Ratio
- RNAZ N/A
- GLMD N/A
- Revenue Growth
- RNAZ N/A
- GLMD N/A
- 52 Week Low
- RNAZ $3.21
- GLMD $2.56
- 52 Week High
- RNAZ $264.00
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- RNAZ 23.15
- GLMD 51.13
- Support Level
- RNAZ $6.63
- GLMD $2.73
- Resistance Level
- RNAZ $8.46
- GLMD $3.07
- Average True Range (ATR)
- RNAZ 1.04
- GLMD 0.23
- MACD
- RNAZ -0.25
- GLMD 0.08
- Stochastic Oscillator
- RNAZ 1.65
- GLMD 66.69
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.